TMPRSS2 and prostate carcinoma: Patients with PRAD showed the highest level of CXCL10 expression at age between 41 and 60 years whereas prostate cancer patients at age 61-80 years showed highest level of expression for TMPRSS2. PRAD patients with Gleason score 10 showed the highest level of expression for CXCL10. On the other hand, expression of TMPRSS2 peaked in patients having Gleason score 7.